Introduction In normal condition, the heart obtains more than two-thirds of its energy from the oxidative metabolism of long chain fatty acids, although a wide variety of substrates such as glucose, lactate, ketone bodies and amino acids are also utilised. In ischaemic myocardium, on the other hand, oxidative metabolism of free fatty acid is suppressed and anaerobic glucose metabolism plays a major role in residual oxidative metabolism. Therefore, metabolic imaging can be an important technique for the assessment of various cardiac diseases and conditions. Materials and methods In SPECT, several iodinated fatty acid traces have been introduced and studied. Of these, 123 Ilabelled 15-(p-iodophenyl)3-R, S-methylpentadecanoic acid (BMIPP) has been the most commonly used tracer in clinical studies, especially in some of the European countries and Japan. Results and discussion In this review article, several fatty acid tracers for SPECT are characterised, and the mechanism of uptake and clinical utility of BMIPP are discussed in detail.
Introduction
The cardiac muscle metabolises a variety of substrates by selecting appropriate ones that are available under the prevailing myocardial condition. In the normal condition, fatty acids and glucose are the most preferred substrates for energy production, followed by lactate, amino acids and ketone bodies. Approximately two-thirds or more of the total energy produced by myocardium is derived from fatty acid oxidation, and most of the remaining energy requirement is covered by glucose metabolism. Both fatty acid and glucose are catabolised to acetyl coenzyme A (acetyl-CoA) through β-oxidation and glycolysis, and the metabolite is oxidised in the tricarboxylic acid (TCA) cycle. In various pathological conditions, the myocardial metabolism can be changed significantly; for instance, in ischaemia, oxidative metabolism of free fatty acids is decreased because β-oxidation of fatty acids in mitochondria requires a large amount of oxygen, and glucose becomes the preferred substrate for anaerobic glycolysis as less oxygen consumption is required [1, 2] . Therefore, different imaging tracers that permit direct assessment of myocardial metabolism are desired to evaluate the pathophysiological changes in various heart diseases. The currently available tracers for metabolic imaging comprise several fatty acid tracers, 18 Ffluorodeoxyglucose (FDG) for the evaluation of glucose metabolism and 11 C-acetate for the assessment of oxygen consumption. Of these tracers, only 123 I-labelled fatty acid tracers are currently available for single-photon emission computed tomography (SPECT) imaging.
lipoproteins. After dissociating from albumin or lipoprotein, fatty acids can pass through the sarcolemmal membrane by diffusion or a facilitated transport mechanism. In the past it has been proposed and believed that passive diffusion is the uptake mechanism. However, absence of uptake of BMIPP in a small minority of patients without any significant cardiac abnormality raised the question of the mechanism of fatty acid transport into the cells [3, 4] . It has been proved that patients with deficient myocardial uptake of BMIPP have type I CD36 deficiency (neither platelets nor monocytes express CD36) [5] [6] [7] , and biopsy specimens from patients with absence of myocardial BMIPP uptake and type I CD36 deficiency demonstrate no expression of CD36 on the myocardial capillary endothelial cells [8] . Positron emission tomography (PET) studies have demonstrated that patients without BMIPP cardiac uptake show a compensatory increase in FDG uptake [9, 10] . Furthermore, the absence of myocardial BMIPP uptake is hereditable [3] and several gene abnormalities related to CD36 deficiency have been reported [11, 12] . Based on these clinical data and other animal experiments, it has been proved that CD36 plays a crucial role in fatty acid transport into the cells [13] . Intracellularly, fatty acids are activated as acyl-CoAs and are consequently trapped inside the cell. This process requires one molecule of adenosine-5′-triphosphate (ATP) for each fatty acid. Then the acyl-CoAs are taken up by mitochondria via an acyl carnitine carrier system and are rapidly catabolised by β-oxidation into two-carbon fragments, acetyl-CoAs, which enter the TCA cycle for further oxidation to become water and carbon dioxide. The half-life of β-oxidation is fast and in the order of minutes, but it is dependent on adequate oxygen availability. The remainder of the total fatty acid entering the myocyte is incorporated into the lipid pool, mainly in the form of triglycerides and phospholipids, or into myocardial structural lipids and presents in the myocardium for a long time. Turnover in the lipid pool is much slower, with a half-life of the order of hours.
Development of iodinated fatty acid compounds for SPECT
In mid 1970s, iodinated long chain fatty acids were developed by introducing radioiodine to the terminal position of fatty acids without altering the extraction efficiency compared with the natural compound [14] [15] [16] . These straight chain fatty acids, 123 I-hexadecanoic acid (IHXA) and 123 I-heptadecanoic acid (IHDA) (Fig. 1) , were proved to be an indicator of myocardial perfusion in the canine model and the human [15, 16] . After rapid initial myocardial extraction, these tracers showed bi-exponential clearance (rapid and slow components) similar to that of 11 C-palmitate. It was generally thought that the rapid and slow components of clearance represented β-oxidation of fatty acids and fatty acid storage in the lipid pool, respectively. However, the ability of these fatty acids to assess myocardial metabolism has been questioned. A canine study revealed that myocardial counts peaked at 5 min after 131 I-IHDA infusion to the left atrium, followed by a decrease with a half-life of 36 min, although the myocardial activity of radiolabelled fatty acids remained constant after an initial increase, indicating that the washout rate of radioactivity from the heart is determined by the back diffusion of deiodinated free iodine, not by β-oxidation [17] .
A clinical study using IHDA demonstrated a high-quality image early after injection, but the image quality deteriorated rapidly because of rapid reduction of myocardial counts and increase in background counts by deiodinated radioiodine [18] . These characteristics of the tracers make IHDA and IHXA unattractive for clinical use, especially for SPECT study.
To overcome the problems associated with these alkyl fatty acids, including release of free iodine resulting in a rapid loss of image quality and poor dependency of the elimination rate on β-oxidation, the phenyl fatty acid was developed by attaching iodide to the para position of phenyl ring (IPPA) [19] (Fig. 1) . Because this agent demonstrates high myocardial uptake and no essential release of free radioiodide into the circulation, the image quality is excellent. Animal experiments demonstrated that IPPA accumulates rapidly in myocardium, followed by a twocomponent tracer clearance similar to that of 14 C-palmitate, permitting estimation of the metabolic rate [20] . The uptake of IPPA during exercise is related to myocardial perfusion and its catabolism follows the usual metabolic pathway for β-oxidation [21] . Through β-oxidation, IPPA is metabolised to iodobenzoic acid and its metabolite iodohippurate, and these are rapidly excreted from the kidneys with the iodine still attached, resulting in high image quality with low background by preventing the buildup of free radioiodide [22] . Coronary occlusion and reperfusion blunt the uptake of IPPA and prolong the clearance, but permanent coronary occlusion decreases the uptake significantly and accelerates the clearance, indicating that IPPA can be used to localise the area of myocardial ischaemia and infarction [23] . For routine clinical use, however, the rate of metabolism and clearance of IPPA is still relatively fast for SPECT imaging, even in a multiple detector SPECT system. For initial IPPA uptake imaging, the acquisition time should be shortened to prevent progressive undersampling due to the rapid count decrease from the myocardium, which results in deterioration in the image quality, and dynamic SPECT study may be necessary for kinetic analysis of β-oxidation. Accordingly, a new fatty acid tracer with more prolonged cardiac retention has been developed to improve quantitative image quality. For this purpose methyl branching was introduced at the β-carbon position to slow myocardial clearance by inhibiting β-oxidation, and two forms of iodine-labelled modified fatty acids, 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) and 15-p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP), were developed [24, 25] (Fig. 1) . In fasted rats, the myocardial half-time values of BMIPP and DMIPP are far higher, at 30-45 min and 6-7 h, respectively, than that of IPPA (5-10 min) [25] . In human, DMIPP showed higher liver uptake than BMIPP (heart/liver ratio 0.39±0.05 and 1.00±0.12, respectively: p<0.001), suggesting that BMIPP is a more favourable cardiac SPECT agent [26] . Especially in Japan and some European countries, BMIPP has since been widely studied to investigate its clinical significance and basic properties.
Another branched fatty acid analogue is a 15-(piodophenyl)-9-(R,S)-methylpentadecanoic acid (9MPA; Fig. 1 ) [27] . This tracer had been designed to be cleared from myocardium at medium rate by introducing a methyl branch at the ninth carbon position, permitting conversion of 9MPA to iodophenyl-3-methyl-nonanoic acid (3MNA) after three cycles of β-oxidation; this water-soluble intermediate metabolite, 3MNA, is rapidly cleared from the myocardium. A clinical trial of this tracer was performed in Japan and abnormal uptake was well described in patients with chronic ischaemic heart disease and acute coronary syndrome [28] [29] [30] . The ability of 9MPA to identify the ischaemic region is comparable to or even better than that of BMIPP [30] ; however, unfortunately, this agent has not been approved for health care services provided by health insurance.
Basic characteristics of 123 I-BMIPP and mechanism of discordant uptake vis-à-vis perfusion tracers Among the various radiolabelled fatty acids, BMIPP has been studied extensively in clinical settings as well as in animal experiments. This compound is designed for SPECT imaging, which requires long myocardial retention of the tracer for good image quality, as described previously. The clinical importance of fatty acid imaging depends on whether incremental information over that supplied by perfusion tracers can be obtained or not. Accumulated clinical experience of BMIPP imaging has demonstrated that discordant BMIPP uptake less than perfusion tracer uptake is often observed in various heart diseases, including in particular ischaemic heart disease, and that this finding may be central in assessing the pathophysiology of the heart condition. Therefore, comparison of BMIPP uptake with that of perfusion tracers is cardinal both in the interpretation and in exploring the clinical utility of BMIPP as a metabolic tracer.
Initial myocardial BMIPP uptake depends on regional perfusion. BMIPP is transported into myocardial cells via fatty acid translocase/CD36 involvement [5, 6, 8, [11] [12] [13] , followed by rapid incorporation into triglycerides through the enzymatic conversion to BMIPP-CoA [25, 31] . A canine study revealed that BMIPP first-pass extraction is rather high, and 74% of BMIPP is extracted from plasma into the myocardium within 30 s of intracoronary BMIPP infusion, followed by a small fraction of washout (8.7% of infused BMIPP) over the next 30 min [32] . The washed out radioactive metabolites consist of back-diffused BMIPP (24% of all washed out radioactivity), α-oxidation metabolite (27%), intermediate metabolites (33%) and full metabolite (16%), suggesting that only a small amount of BMIPP-CoA transported into mitochondria is metabolised by α-oxidation (because first β-oxidation is blocked by β-methyl branching), followed by β-oxidation. The high uptake and low washout of the tracer indicate that BMIPP can be substantially considered as a metabolically trapped tracer like FDG. Early washout from the myocardium may reflect back diffusion of non-metabolised BMIPP. Severe ischaemia with 30-min coronary occlusion and reperfusion was found to increase early back diffusion of non-metabolised BMIPP from 25.1% to 34.7%, and in mild ischaemia (10-min occlusion) back diffusion of BMIPP was closely correlated with lactate production (a marker of ischaemic severity) [33] .
Etomoxir, a carnitine palmitoyltransferase I inhibitor that inhibits the transport of long chain lipids into the mitochondria, enhanced early washout (until 8 min after injection) of radioactivity owing to increased back diffusion of BMIPP (25.1% to 41.9%) [34] . These authors speculated that this early 8-min washout period in dogs might correspond to the usual SPECT initiation time in human (around 15-20 min after injection of BMIPP). If so, clinical BMIPP SPECT imaging represents the BMIPP retention status after the completion of the non-metabolised BMIPP back diffusion. In the first step of the common pathway of fatty acid metabolism, BMIPP is also converted to BMIPP-CoA by consuming ATP; once BMIPP-CoA is synthesised, it is hardly back-diffused out of the cell and is retained within it [35, 36] . Therefore, the ATP level of the cells may be related to the amount of BMIPP back diffusion or, in other words, BMIPP myocardial retention. BMIPP uptake was found to correlate with the ATP level in mouse myocardium treated with an electron transport uncoupler, dinitrophenol, which reduced the intracellular ATP level without affecting acylCoA synthetase activity or CoA level [37] . In acutely damaged canine myocardium introduced by coronary occlusion and reperfusion, BMIPP uptake also correlated with the tissue ATP levels [38] .
In a clinical study with dynamic SPECT, BMIPP washout was observed early after BMIPP injection (2-6 min after injection) in the segments with reversible thallium defects but not in the segments with normal thallium uptake and fixed thallium defects [39] . In addition, early dynamic BMIPP SPECT images in acute coronary syndrome showed similar BMIPP uptake and thallium uptake, although discordant BMIPP uptake less than thallium uptake was observed in conventional 30-min BMIPP images [40] . These clinical and animal experimental findings suggest that, in ischaemic myocardium, initial myocardial distribution of BMIPP may represent blood flow, followed by back diffusion of free BMIPP which is not incorporated into the triglyceride pool after conversion to BMIPP-CoA, resulting in discordant BMIPP uptake less than thallium uptake on static images obtained 20-30 min after BMIPP injection.
In contrast, during the acute phase of ischaemia, reduced availability of oxygen suppresses β-oxidation and increases the proportion of fatty acid in the triglyceride pool. At this time, BMIPP may enter this enlarged triglyceride pool. Accordingly, BMIPP uptake may be increased in acute ischaemia [41, 42] . Early canine experiments using the occlusion and reperfusion model showed higher BMIPP uptake than thallium uptake (reverse mismatch), which is the opposite finding to that observed in clinical studies [41, 43] . BMIPP injection after 15-or 60-min coronary occlusion and 3-h reperfusion demonstrated that BMIPP uptake in triphenyltetrazolium chloride (TTC)-positive areas was 27% higher than that in TTC-negative areas and 9% higher than that in the normal area after normalisation by perfusion, suggesting that BMIPP uptake exceeding perfusion tracer uptake during the acute phase of post ischaemia is characteristic of ischaemically stunned but viable myocardium [41] . However, BMIPP uptake may change as a function of time after ischaemia. A recent rat study with 20-min coronary occlusion and reperfusion demonstrated that BMIPP uptake was higher than thallium uptake at 1 day after reperfusion but similar to or lower than thallium uptake at 5 days after reperfusion [44] . In addition, another rat study with 20-min coronary occlusion and reperfusion revealed BMIPP uptake to be higher than thallium uptake at 20 min and 1 day after reperfusion, followed by similar uptake at 3 days after reperfusion and significant reduction in BMIPP uptake compared with that of thallium at 7 days after reperfusion; however, BMIPP uptake had recovered to the normal level at 30 days after reperfusion [45] . Furthermore, a clinical study in patients with stunned myocardium showed that reduction in BMIPP uptake in the area at risk was minimal within 27 h of onset but significant after 5-12 days, with normalisation at 1 month [46] . These findings indicate that BMIPP imaging may offer metabolic information independent of perfusion at different stages of ischaemic insults. The usual mismatch seen in clinical studies, with discordant BMIPP uptake less than perfusion tracer uptake, may reflect the myocardial alteration during the subacute phase of ischaemia or cumulative or chronic ischaemic status. Although most instances of discrepant uptake of BMIPP and perfusion tracers observed in daily clinical practice involve lower BMIPP uptake, occasionally the converse is seen, with BMIPP uptake exceeding perfusion tracer uptake (reverse mismatch). In normal subjects, % uptake of BMIPP is higher than that of thallium in the septum to the inferior wall [47] , and most cases of reverse mismatch are observed in the inferior septum to the inferior wall in patients with coronary artery disease [48] [49] [50] , suggesting that reverse mismatch in these areas may be generated by the greater photon attenuation of thallium compared with 123 I. Such an artefact might be reduced by using 99m Tc-labelled perfusion tracers instead of thallium, and it has been proposed that scatter correction is effective in enabling accurate comparison of BMIPP and 99m Tc-MIBI [51] .
Clinical utility of 123 I-BMIPP imaging

Acute myocardial infarction
In patients with coronary artery disease, discrepant uptake between BMIPP and thallium was reported initially in patients with acute myocardial infarction. Tamaki et al. found discordant BMIPP uptake less than thallium uptake in 17 of 28 patients with myocardial infarction. Such discordant BMIPP uptake was observed more often in areas of acute than chronic myocardial infarction (59% at <4 weeks versus 31% at >4 weeks after onset), and more often in areas supplied by revascularised arteries than in areas supplied by nonrevascularised arteries (74% versus 28%). In addition, regional wall motion was more severely impaired in such areas of perfusion-metabolism mismatch [50] . A comparison between BMIPP and 99m Tc-MIBI uptake 4-10 days after coronary thrombolysis demonstrated that the segments with a greater reduction in BMIPP uptake than in MIBI uptake (mismatch) either showed normal wall motion or demonstrated inotropic reserve during dobutamine stimulation [52] . These findings suggested that mismatch is indicative of jeopardised but viable myocardium and may correspond to stunned myocardium where functional abnormality is prolonged in association with sustained metabolic abnormalities (metabolically stunned myocardium) after successful reperfusion procedures have resulted in recovery of perfusion (Fig. 2) . Several studies have supported this concept, in that, areas of discordant BMIPP uptake less than perfusion tracer uptake in the acute or subacute stages of myocardial infarction demonstrated improvement of wall motion abnormality at subsequent follow-up periods [53] [54] [55] [56] [57] [58] [59] [60] . These studies also indicated that mismatched BMIPP uptake less than perfusion tracer uptake may be a predictor of functional recovery in acute myocardial infarction. Reduction of BMIPP uptake has also been shown to be useful for evaluation of the area at risk in acute myocardial infarction. BMIPP defect size in the subacute phase of myocardial infarction correlated well with the risk area revealed by contrast ventriculography or echocardiography [56, 61] , and the area with reduction in BMIPP uptake 1 week after the onset of myocardial infarction corresponded well to the area with perfusion defect demonstrated before revascularisation therapy at admission [62] . These observations suggest that BMIPP imaging obtained in the subacute phase of myocardial infarction can be called "ischaemic memory imaging" because it reflects prior ischaemic damage or metabolically stunned myocardium even after the restoration of perfusion [56, 63, 64] .
In the chronic phase of myocardial infarction, mismatched uptake of BMIPP less than thallium uptake is not an uncommon finding. A study by Matsunari et al. compared resting BMIPP uptake and exercise-redistribution thallium scintigraphy in 26 patients with prior myocardial infarction (>4 weeks after onset) without revascularisation therapy. Sixty-seven percent of the segments with discordant BMIPP uptake less than redistribution thallium uptake showed reversible thallium defects, 21% showed fixed thallium defects and 12% showed normal thallium uptake, indicating that the myocardium with mismatched BMIPP uptake less than redistribution thallium uptake were mostly exposed to stress-induced ischaemia [39] . In the subacute to chronic Tctetrofosmin (TF), 123 I-BMIPP and gated blood pool images. The patient was admitted with acute myocardial infarction (AMI) and emergency coronary angiography revealed 90% stenosis of the proximal left anterior descending coronary artery. Direct angioplasty was performed successfully. Maximum creatine kinase was 460 IU/l. Gated blood pool study demonstrated severe hypokinesis of the apex to the anteroseptal wall at 3 days after the onset of AMI. Six days after the onset, tetrofosmin did not show a definite perfusion abnormality, though reduced BMIPP uptake was noted in the anteroseptal wall. Three months later, BMIPP uptake had improved and wall motion abnormality had disappeared. The area with discordant BMIPP uptake less than perfusion tracer uptake may represent metabolically and functionally stunned myocardium and indicate the area at risk as an "ischaemic memory". ED end diastole, ES end systole phase of infarction (>2 weeks after onset), similar findings were reported, with most of the mismatched segments (22/ 27) associated with a reversible thallium defect [65] .
Unstable angina pectoris
Mismatched BMIPP uptake less than thallium uptake has also been observed frequently in patients with unstable angina [66] [67] [68] [69] . Comparison of BMIPP images in 19 patients with unstable angina without prior myocardial infarction and stress thallium scans performed after stabilisation of their condition demonstrated that BMIPP decrease was associated with stress perfusion abnormality in 44 of 57 (77%) segments and that degree of BMIPP reduction correlated with the degree of perfusion abnormality at stress, the degree of wall motion abnormality and the severity of coronary artery stenosis [66] . BMIPP imaging performed in 20 patients with unstable angina after medication and elimination of chest pain disclosed that patients with abnormal BMIPP uptake (n=11) had more severe coronary artery stenosis exceeding 90% (10/11 vs 4/ 9), 99% stenosis (9/11 vs 0/9) and more collateral opacification (4/11 vs 0/9) than patients without BMIPP abnormality (n =9). In addition, revascularisation was performed in 82% of patients with abnormal BMIPP images but in only 22% of patients with normal BMIPP images; accordingly, BMIPP imaging may be helpful in decision-making regarding interventional treatment [68] . In a study of 111 consecutive patients with acute chest pain without myocardial infarction, BMIPP imaging (performed 2 days after chest pain) abnormality was observed in 74% of coronary abnormalities, while only 38% showed an abnormality on tetrofosmin imaging (performed within 24 h after chest pain) [70] . These findings indicate that reduced BMIPP uptake in patients with unstable angina may represent persistent metabolic abnormality reflecting prior severe ischaemia or repetitive ischaemic insults; thus the concept of ischaemic memory imaging could be extended and applied to this patient population. In other words, BMIPP imaging could extend the time window for detecting a previous ischaemic event after resolution of the perfusion abnormality. In addition, the concept of ischaemic memory can be applied to patients with vasospastic angina pectoris. In these patients, repetitive ischaemia may cause metabolic alteration and this metabolic alteration can be detected as a reduction in BMIPP uptake; however, stress perfusion SPECT often fails to detect ischaemia because exercise or vasodilator stress usually does not provoke vasospasm. Accordingly, BMIPP imaging should be considered as one of the non-invasive diagnostic methods [71] .
Chronic coronary artery disease
In chronic stable coronary artery disease even without a history of myocardial infarction, discordant BMIPP uptake I-BMIPP and gated blood pool images. The patient, with diabetes mellitus and nephrotic syndrome, had an electrocardiographic abnormality; therefore, thallium and BMIPP SPECT were performed. Discordant BMIPP uptake less than thallium uptake in the apex to the anteroseptal wall was observed, and the area demonstrated severe hypokinesis on gated blood pool scintigraphy. Coronary angiography showed left anterior descending coronary artery (LAD) obstruction and 90% stenosis of the left circumflex coronary artery. Coronary angioplasty (PTCA) of the LAD was performed successfully and BMIPP uptake and wall motion abnormality improved 1 month later. The discordant BMIPP uptake less than thallium uptake depicted the dysfunctional but viable myocardium or hibernating myocardium in the apex to the anteroseptal wall. ED end diastole, ES end systole less than perfusion tracer uptake is not a rare finding (Fig. 3) . Comparison between BMIPP uptake and stress-reinjection thallium SPECT in 45 patients with chronic coronary artery disease demonstrated that most of the segments (118/124) with discordant BMIPP uptake less than re-injection thallium uptake were associated with reversible thallium defects, indicating ischaemic myocardium [48] . When reversible thallium defects were analysed, 118 out of 237 segments evidenced discordant BMIPP uptake less than re-injection thallium uptake, suggesting that approximately half of the segments with ischaemic myocardium have a more severe metabolic abnormality than would be expected from the degree of resting perfusion abnormality. On the other hand, 71 (79%) of 90 segments with fixed thallium defects demonstrated concordant uptake of both tracers, suggesting that myocardium with poor viability has a metabolic abnormality similar to the degree of resting perfusion abnormality. When reversible thallium defects were analysed with respect to evidence of discordant BMIPP uptake less than thallium uptake and regional wall motion abnormality, wall motion was more severely impaired in the segments with discordant BMIPP uptake less than thallium uptake than in those without such discordance among both patients with and patients without old myocardial infarction. However, severity of coronary artery stenosis was similar in vascular territories with discordant BMIPP uptake less than re-injection thallium uptake and in those without such discordance.
Similar findings were reported in 12 patients with stable angina without prior myocardial infarction: the location and degree of BMIPP decrease were associated with those of stress-induced hypoperfusion on thallium imaging, but no significant correlation was found between BMIPP reduction and coronary artery stenosis [66] . In 55 patients with stable coronary artery disease who had persistent thallium defects in at least one segment on stress-redistribution thallium imaging, BMIPP uptake in the segments with new fill-in after thallium re-injection was investigated [72] . Discordant BMIPP uptake less than thallium uptake was observed in 37% of segments with thallium redistribution after exercise whereas it was seen in 82% of segments with no redistribution but new fill-in after thallium re-injection. In addition, such discordance was observed in only 19% of the segments with fixed defects. In previous studies using stress-redistribution-re-injection thallium SPECT, the myocardium with new fill-in after thallium re-injection was characterised as severely ischaemic but viable myocardium with frequent wall motion abnormalities that may recover after revascularisation [73, 74] . Accordingly, these observations may indicate that mismatched uptake is suggestive of myocardium jeopardised by more severe ischaemia.
The concept of ischaemic memory imaging using BMIPP has been tested in 32 patients with exerciseinduced ischaemia on thallium SPECT by injecting BMIPP at rest within 30 h of ischaemia which was induced and confirmed by exercise thallium SPECT [75] . In more than 90% of the patients, BMIPP identified an area of suppressed fatty acid uptake corresponding to the ischaemia detected by stress thallium study up to 30 h after the ischaemic episode; therefore, the authors concluded that BMIPP SPECT can offer ischaemic memory imaging, identifying sustained metabolic abnormality until at least 30 h after stress-induced ischaemic episodes. Accumulated data in patients with chronic ischaemic heart disease in Japan, however, have demonstrated that reduced BMIPP uptake is frequently observed independent of prior radionuclide and ECG stress tests but in relation to severe ischaemia and wall motion abnormality; this raises the possibility that BMIPP reduction reflects the substrate shift from fatty acid to glucose as a result of repeated myocardial ischaemia rather than the single episode of metabolic stunning. Myocardium exposed to repetitive ischaemia or stunning is subsequently adapted metabolically into chronic ischaemic myocardium, so-called hibernating myocardium [76] [77] [78] . In hibernating myocardium, energy substrate is shifted from fatty acid to glucose, contractility is impaired but with recruitable inotropic reserve, and myocardial flow reserve is severely impaired. In relation to this issue, a recent investigation of the relationship between BMIPP uptake and myocardial blood flow measured by PET in patients with chronic stable angina without previous myocardial infarction demonstrated that rest myocardial blood flow was preserved independent of BMIPP uptake. However, hyperaemic myocardial blood flow was decreased in the area with reduced BMIPP uptake, with the consequence that the severity of impaired myocardial flow reserve correlated with the reduction in BMIPP uptake [79] . Hence, reduced BMIPP uptake implies impaired myocardial flow reserve and may reflect substrate shifts in hibernating myocardium.
Viability assessment and prediction of functional recovery in chronic coronary artery disease Improvement of regional or global systolic function can be achieved if revascularisation of viable myocardium is successfully performed. Therefore, assessment of residual myocardial viability in the setting of dysfunctional myocardium due to significant coronary artery disease is a key issue in making clinical decisions with respect to revascularisation procedures. On scintigraphy using perfusion tracers, the hallmarks of myocardial viability supplied by a stenosed or occluded coronary artery are a perfusion defect with thallium redistribution on stress-redistribution or rest-redistribution images, fill-in of thallium, sestamibi or tetrofosmin after re-injection, and significant uptake on resting or re-injection images (usually more than 50-60% of the uptake in the normal area). However, the ability of perfusion tracers to differentiate viable from non-viable myocardium is not completely satisfactory, as evidenced by recent viability studies using perfusion tracers [80, 81] .
In chronic coronary artery disease, the hallmark of viability using perfusion tracers is significant tracer uptake, although the hallmark of viability on BMIPP imaging is the relative reduction in BMIPP uptake compared with perfusion tracer uptake. There are several substantial lines of evidence that discordant BMIPP uptake less than perfusion tracer uptake is a marker of viability. Firstly, as previously described, such mismatch is associated with ischaemic myocardium as evidenced by stress perfusion studies. Secondly, increased FDG uptake has been observed in areas with discordant BMIPP uptake less than thallium uptake, and higher oxidative metabolism on 11 C-acetate PET was observed in the mismatched area than in the area with concordant reduction of BMIPP and perfusion [82] . Thirdly, myocardial areas with BMIPP uptake less than sestamibi uptake were more likely to have a positive response to dobutamine than areas with a matched defect [83, 84] . Lastly, histological examination in patients with bypass surgery demonstrated that while the relative uptake of BMIPP (%BMIPP) correlated with the percentage of fibrosis (% fibrosis), the change in %BMIPP looked biphasic. When fibrosis was <20%, there was a steep reduction in BMIPP uptake, although thallium uptake reduction correlated linearly with % fibrosis. Thus, areas with discordant BMIPP uptake less than thallium uptake had less than 20% fibrosis [85] .
More directly, functional recovery after revascularisation has been investigated in relation to BMIPP uptake abnormality. In patients with chronic stable coronary artery disease, discordant BMIPP uptake less than thallium uptake predicted functional recovery after revascularisation more precisely than could exercise-re-injection thallium study. In addition, the extent of discordant uptake of BMIPP less than re-injection thallium uptake before revascularisation was a good predictor of the improvement in global ejection fraction after revascularisation [86] . Similarly, in patients with chronic ischaemic left ventricular dysfunction, the area with discordant BMIPP uptake less than sestamibi uptake measured by quantitative analysis was highly predictive of improvement in ejection fraction, wall motion and free fatty acid utilisation after revascularisation [84] . Interestingly, comparison of FDG, BMIPP and sestamibi uptake in patients with old myocardial infarction and stable ischaemic regional wall motion abnormalities demonstrated that the extent of discordant BMIPP uptake less than FDG uptake before revascularisation correlated highly with ejection fraction improvement after revascularisation (r=0.74) and also that the extent of discordant BMIPP uptake less than sestamibi uptake correlated significantly with ejection fraction improvement (r=0.50). However, no significant correlation was observed between the area with discordant FDG uptake more than sestamibi uptake and ejection fraction recovery [87] . The results are quite intuitive because, in ischaemic and viable myocardium, substrate shift from fatty acid to glucose would take place; hence, mismatch of FDG and BMIPP uptake should be prominent but mismatch between BMIPP and sestamibi might be modest. These data suggest that discordant BMIPP uptake less than perfusion tracer uptake may represent reversible ischaemic myocardial injury or hibernating myocardium and that the regional and global dysfunction will improve after revascularisation in patients with chronic stable coronary artery disease.
Risk stratification and prognostic value
Assessment of the prognostic value of BMIPP imaging over perfusion tracers in patients with coronary artery disease is a matter of clinical importance. An initial study in 50 consecutive patients with myocardial infarction was performed to investigate the prognostic implications of BMIPP and stress-re-injection thallium imaging (obtained at 2 weeks to 6 months after infarction) with a mean follow-up period of 23 months [88] . During the follow-up period, nine patients had cardiac events; eight of these nine patients showed discordant BMIPP uptake less than re-injection thallium uptake, whereas only 20 of 41 patients without cardiac events did so. When all the clinical and radionuclide variables were analysed by Cox regression analysis, presence of discordant BMIPP uptake was the best, and an independent, predictor of future cardiac events, followed by the number of coronary stenoses. BMIPP and thallium imaging performed within 1 month of acute myocardial infarction demonstrated that impaired BMIPP uptake and mismatched BMIPP uptake less than thallium uptake are related to a high probability of fatal and nonfatal cardiac events [89] , and the defect score of BMIPP and mismatched BMIPP uptake less than thallium uptake provided incremental predictive value for future cardiac events [90] .
The clinical value of BMIPP imaging has also been demonstrated in patients with the chronic stage of myocardial infarction. Fukuzawa et al. performed BMIPP imaging before revascularisation in 76 patients with chronic stable ischaemia (including 61 patients with myocardial infarction after at least 3 months following onset) and left ventricular dysfunction [91] . Patients with a large amount of discordant BMIPP uptake less than thallium uptake demonstrated a greater improvement in ejection fraction after revascularisation and, interestingly, showed significantly better event-free survival than patients with a small amount or no perfusion-metabolism mismatch. These data indicate that patients with a significant amount of discordant BMIPP uptake less than thallium uptake may benefit from revascularisation.
It has also been demonstrated that BMIPP imaging is valuable for risk stratification in chronic coronary artery disease without old myocardial infarction. In 270 patients with known or suspected coronary artery disease without previous myocardial infarction, the BMIPP defect score was analysed with respect to cardiac events during a median follow-up of 3.9 years [92] . Kaplan-Meier survival estimates revealed a hard event-free survival rate of 98% at 3 years in patients with a summed BMIPP defect score lower than 5 but 93% in those with a defect score of 5 or greater (p=0.03). Similarly, the all event-free survival rate was 92% at 3 years in patients with a summed BMIPP defect score lower than 5 but 80% in those with a defect score of 5 or greater (p=0.0003). More importantly, BMIPP was able to select a high-risk subgroup among patients with diabetes mellitus as well as non-diabetic patients, with an event rate of 41% in diabetic patients with a BMIPP defect score of 5 or more but only 4% in non-diabetic patients with a BMIPP defect score lower than 5. This ability of BMIPP imaging to offer risk stratification in diabetic patients is advantageous compared with FDG PET imaging, because unlike FDG uptake, myocardial BMIPP uptake is not affected by blood substrate contents [93, 94] .
Another strength of BMIPP imaging is its simplicity since it offers metabolic information without a stress procedure. It is a matter of great interest whether resting BMIPP imaging offers complementary prognostic information to that provided by conventional stress perfusion imaging. One hundred and sixty-seven consecutive patients with angina pectoris but without prior myocardial infarction who had undergone both BMIPP and stress thallium imaging were followed up for 48 months [95] . For overall cardiac events (five hard and 29 soft events), multivariate Cox's analysis revealed that reduced BMIPP uptake, stress perfusion score, diabetes and left ventricular ejection fraction were the significant predictors. No hard event was observed with normal BMIPP uptake, whereas two patients with nearly normal stress perfusion with impaired BMIPP uptake had a hard event. The authors concluded that resting BMIPP imaging may provide significant prognostic information independent of stress myocardial perfusion imaging.
Cardiomyopathy
In patients with cardiomyopathy, evaluation of the metabolic status in addition to perfusion may offer clues regarding the underlying pathophysiology. Animal experiments with autoradiography using methyl-branched fatty acids in cadiomyopathic hamsters and hypertensive rats demonstrated that fatty acid uptake was heterogeneous and lower than thallium uptake in endocardium [96] [97] [98] [99] [100] . In patients with cardiomyopathy, including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), it has been reported that BMIPP distribution is inhomogeneous, and discordant BMIPP uptake less than thallium uptake is a general finding especially in patients with HCM (Fig. 4) . In patients with HCM, discordant BMIPP uptake less than thallium uptake in the disproportionately thickened septum is a common finding [101, 102] , and mismatched BMIPP uptake less than thallium uptake in the hypertrophied septum and the degree of BMIPP abnormality have been found to be correlated with the severity of hypertrophy [103] . In addition, BMIPP accumulation is significantly less in the septal portion of the anterior and the posterior wall and the apex than in the lateral segments. Patients with such BMIPP defects in the septal portion of anterior and posterior segments were found to have a more frequent family history of HCM, sudden death and severe cardiac dysfunction [104] , and the severity of BMIPP abnormality is a significant predictor of cardiac events, including heart failure and cardiac death [105, 106] .
Several studies employing stress thallium scintigraphy in patients with HCM have revealed that, despite the normal epicardial coronary arteries, the reversible perfusion defect is a common finding, which can be eliminated by verapamil, and that ischaemia may account for the phenomenon [107] [108] [109] . When the relationship between BMIPP uptake and ischaemia defined by the reversible perfusion defect on stress-redistribution thallium scintigraphy in HCM patients was investigated, mismatched BMIPP uptake less than thallium uptake in hypertrophied areas often accompanied reversible thallium defects [102, 110] . Furthermore, BMIPP imaging depicts disease-associated abnormality even at early stages [102] . Of five patients with NYHA class 1, all five showed normal stress thallium uptake and only one showed Tl and 123 I-BMIPP in patients with HCM. There was increased thallium uptake in the apex to the anteroseptal wall, but BMIPP uptake was reduced in that area. Discordant BMIPP uptake less than thallium uptake in the hypertrophic area is a rather early phenomenon of HCM reduced BMIPP uptake. Of six patients with NYHA class 2, all showed reduced BMIPP uptake less than redistribution thallium uptake, four showed stress-induced ischaemia in the mismatched area and two showed normal thallium findings. Of six patients with NYHA class 3, all showed reduced BMIPP uptake less than redistribution thallium uptake, with four showing an additional matched defect simultaneously and only two showing stress-induced ischaemia in the mismatched area. Together with other recent studies, the discordant BMIPP uptake less than thallium uptake in hypertrophic areas with a high frequency of reversible thallium defects suggests that myocardial ischaemia or impaired coronary flow reserve may play a considerable role in impaired fatty acid utilisation or metabolism [110, 111] and that mismatched uptake may be an early marker of HCM, followed by a matched defect at a later stage [102] . A recent study with PET demonstrated that, in patients with HCM, the reduction in BMIPP uptake was the most sensitive indicator of metabolic abnormalities, followed by the abnormal oxidative metabolism and FDG uptake [112] . Regarding the ventricular function in patients with HCM, BMIPP uptake abnormality was found to correlate well with regional function and also with global ejection fraction, while thallium abnormality did not; hence the ventricular function correlated more closely with metabolic abnormality than with perfusion abnormality [113] [114] [115] [116] .
In patients with DCM, both BMIPP and thallium distribution is heterogeneous, and BMIPP abnormality correlates well with ventricular dysfunction, whereas thallium abnormality does not [117] . In addition, the extent of the BMIPP abnormality reflects the severity of haemodynamic deterioration and histopathological changes [118] . BMIPP imaging is useful for therapy monitoring and risk stratification in DCM patients. Reduction in BMIPP uptake in patients with DCM has been found to be predictive of the response to β-blocker therapy [119, 120] ; paradoxically, however, while responders showed no significant changes in the heart to mediastinum ratio over 6 months, non-responders showed a significant increase, suggesting that β-blocker therapy may lead to metabolic improvement even without functional improvement [120] . On the other hand, Ito et al. found that myocardial BMIPP uptake improved significantly at 6 months in responders to β-blocker therapy but not in nonresponders [121] . Following treatment with coenzyme Q10, BMIPP uptake abnormality in patients with DCM improved, while the percent fractional shortening measured by echocardiography did not change, suggesting that BMIPP imaging could be a more sensitive indicator of response than functional parameters [122] . These data indicate that BMIPP uptake may predict the response to β-blocker therapy in DCM; however, further investigation is warranted to assess the role of BMIPP imaging in the monitoring of therapeutic effect.
BMIPP imaging might provide helpful information for the differential diagnosis of patients with severe LV dysfunction. Ischaemic cardiomyopathy and DCM are the main causes of congestive heart failure and share similar clinical features, such as dilated ventricles and diffuse hypokinesis with a severely reduced ejection fraction. However, the therapeutic approach in the two diseases is quite different. When discordant BMIPP uptake less than thallium uptake was investigated, ischaemic cardiomyopathy and the dilated form of HCM showed a high prevalence of mismatched uptake, while idiopathic DCM and alcoholic and hypertensive cardiomyopathy showed a lower incidence of mismatched uptake [123] .
Transient left ventricular apical ballooning is a newly defined syndrome in Japan and has been called takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome. It is characterised by sudden onset of chest symptoms, electrocardiographic changes, transient left ventricular wall motion abnormalities particularly involving in the apical region, low-grade cardiac enzyme elevation and absence of significant coronary stenosis [124, 125] . In the subacute phase (around 5 days after onset), reduction in thallium uptake is mild but marked BMIPP uptake reduction is observed in the regions with an apical asynergy. Resolution of apical asynergy is observed around 15 days after onset, while normalisation of impaired BMIPP uptake is observed after about 1 month [126] . A recent study demonstrated that tetrofosmin uptake immediately after the onset was severely depressed in the area that corresponded to the large apical dysfunction. The tetrofosmin uptake abnormality and apical dysfunction recovered rapidly at the subacute stage, but BMIPP abnormality persisted for a longer period [127] . These findings suggest that the transient ventricular dysfunction in this disease may essentially be stunned myocardium, although the aetiology is still unknown.
Conclusions
In the normal condition, approximately two-thirds or more of the total energy produced by the myocardium is derived from fatty acid oxidation, and myocardial substrates may change significantly in various pathological conditions such as ischaemia. Accordingly, many fatty acid tracers have been introduced for SPECT imaging. However, straight chain fatty acid analogues have not been used widely in clinical studies because of their rapid washout, which renders them unsuitable for SPECT imaging. In contrast, methyl branched fatty acid analogues permit SPECT imaging more easily because of their prolonged myocardial retention. BMIPP, one of the methyl branched fatty acid analogues, is the only fatty acid tracer approved for daily clinical use at present. The concept underlying BMIPP imaging is metabolic trapping, as with FDG, by inhibition of β-oxidation through the introduction of methyl branching at the β-carbon position. Myocardial BMIPP uptake probably reflects activation of BMIPP into BMIPP-CoA and, indirectly, cellular ATP production by fatty acid metabolism. Hence, under the condition of ischaemia, a reduction in BMIPP uptake is observed, reflecting the reduction in ATP production due to depressed oxidative fatty acid metabolism and substrate shift from fatty acids to glucose. Reduced utilisation of fatty acids or reduced uptake of BMIPP at rest is often observed in ischaemic myocardium independent of the uptake of perfusion tracers. Through comparison with perfusion, BMIPP imaging enables "ischaemic memory imaging", with detection of previous myocardial ischaemia (metabolically stunned myocardium) and viable but chronically dysfunctional myocardium (hibernating myocardium). In addition, BMIPP imaging may offer incremental prognostic information in ischaemic heart disease. In cardiomyopathy, BMIPP imaging may be useful for the early detection of HCM and differentiation of ischaemic cardiomyopathy from idiopathic DCM, and also for the prediction of prognosis. Through basic and clinical studies, it has become clear that BMIPP imaging has high potential utility in clinical nuclear cardiology practice. Thus worldwide clinical use of fatty acid imaging is desirable.
